Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACADIA Pharmaceuticals Inc (ACAD) -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (448)	12/12/2007 5:28:47 PM
From: Ian@SI	Respond to of 588

Answering my own Q, I should have looked first... ++++++++++++++++++++ ACADIA Pharmaceuticals upgraded to "strong buy" - update Wednesday, December 12, 2007 1:39:45 PM ET JMP Securities NEW YORK, December 12 (newratings.com) - Analysts at JMP Securities upgrade ACADIA Pharmaceuticals Inc (ACAD.NAS) from "market outperform" to "strong buy." The target price is set to $21. In a research note published this morning, the analysts mention that the poster presentation of the Phase II trials of pimavanserin for combination treatment of schizophrenia were in-line with the top-line results released earlier in March. The data showed statistically significant improvement of antipsychotic efficacy and an improved safety profile, the analysts say. The new data also revealed cognitive improvements after only six weeks, JMP Securities adds. The positive data could help to attract a large pharmaceutical or biotech partner for the Phase III trials and commercialization of the drug, the analysts point out. The recent pressure on ACADIA Pharmaceuticals’ share price has made the current valuation of the company’s stock even more attractive than earlier, JMP Securities says.